Alle Studien
RekrutierungBEOBACHTEND

PASS of Xromi Comparing Safety and Effectiveness in Children Under 2 Years With Sickle Cell Disease [PRECISE PASS]

This study, called PRECISE PASS, is looking into a medicine called Xromi (hydroxycarbamide oral solution) for babies and toddlers aged 9 months to just under 2 years old who have sickle cell disease. Its main goal is to check how safe Xromi is and how well it helps control the condition in real-life situations. Researchers will follow a group of children who are given Xromi and compare them to a similar group of children who haven't taken this medicine. They will be observed for 24 months. By comparing these groups, doctors hope to learn more about the benefits and any possible side effects of Xromi for these very young patients, using information from their regular doctor visits.

Auf einen Blick

Status
Rekrutierung
Sponsor
Nova Laboratories Limited
Einschreibeziel
180
Starten
09 Jun 2025
Geschätzte Fertigstellung
01 Jun 2029

Worum geht es in dieser Studie?

Sickle cell disease is a lifelong condition that affects red blood cells. It can cause a lot of pain and other serious problems. Xromi is a medicine designed to help manage sickle cell disease and reduce these complications. This particular study, called PRECISE PASS, is focusing on very young children, specifically those aged 9 months up to their second birthday.

The main purpose of this study is to carefully watch children taking Xromi and see how safe it is for them, as well as how well it works in everyday medical care. They want to understand if there are any side effects and if it genuinely helps children with sickle cell disease. The study will look at children already prescribed Xromi and compare them to children who have not received this treatment. This comparison helps researchers understand Xromi's effects better.

Researchers will follow these children for two years (24 months), collecting information from their regular visits to the doctor. It's important to know that this isn't a study where new treatments are tested. Instead, it observes how Xromi is used in usual medical practice. The study aims to provide important information to doctors and families about using Xromi safely and effectively in very young children with sickle cell disease.

Wichtige Erkenntnisse

  • Study examines Xromi's safety and effectiveness in children under 2 with sickle cell disease.
  • Compares children taking Xromi to those not taking it, using routine medical data.
  • Children are followed for 24 months (two years).
  • No extra treatments or appointments are needed for the study.
  • Aims to improve understanding of Xromi for this young age group.
  • Participation is voluntary and can be withdrawn at any time.

Wer könnte berechtigt sein?

To be considered for the group taking Xromi, your child must be between 9 months and just under 2 years old, have sickle cell disease, and have been prescribed Xromi to help manage their condition. It's also important that they haven't taken any form of hydroxycarbamide before and aren't getting regular blood transfusions every 8 weeks or more often. Your child also shouldn't have specific serious liver or kidney problems, very low blood cell counts, other active serious illnesses, or be on certain other medications like those for HIV. You, as the parent or legal guardian, would need to give your permission for your child to be part of the study.

For the comparison group, children need to be between 9 months and just under 2 years old with sickle cell disease and haven't had Xromi or similar medicines. These children will be chosen to closely match the children taking Xromi in terms of age and their specific type of sickle cell disease. Again, parent or guardian permission is needed.

Könnte diese Studie für Sie geeignet sein?

Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.

  1. Is your child between 9 months and just under 2 years old?
  2. Does your child have sickle cell disease?
  3. Has your child been prescribed Xromi, or have they never taken similar medication?
  4. Has your child received regular blood transfusions every 8 weeks or more often?
  5. Does your child have specific serious liver/kidney problems, very low blood counts, or other serious health issues?
Beantworten Sie jede Frage, um Ihr Ergebnis zu sehen.

Was beinhaltet die Teilnahme?

If your child takes part, they will either be in the group already prescribed Xromi or a comparison group that hasn't taken it. No new treatments or extra tests will be given specifically for this study. The researchers will simply collect information from your child's regular medical notes and clinic visits over a period of 24 months, starting from when they began Xromi or a similar 'start date' for the comparison group. You won't need to attend any extra appointments or do anything special just for the study; all information comes from your child's usual care. The study is planned to take place in specialised hospitals in the UK and Germany, and possibly other European countries.

Potenzielle Risiken und Vorteile

Being part of this study helps doctors learn more about how Xromi works in young children, which could benefit others with sickle cell disease in the future. As this study collects information from routine care, there are no additional medical risks from participation beyond what is already involved in your child's standard treatment for sickle cell disease. You or your child's doctor can decide to withdraw your child from the study at any time, without it affecting their medical care.

Standorte (12)

  • Universitätsklinikum Hamburg-Eppendorf
    Verifizierte Postleitzahl
    Hamburg, Deutschland· Rekrutierung
  • Universitätsklinikum Heidelberg
    Verifizierte Postleitzahl
    Heidelberg, Deutschland· Rekrutierung
  • Basildon University Hospital
    Verifizierte Postleitzahl
    Basildon, Vereinigtes Königreich· Rekrutierung
  • Noah's Ark Children's Hospital for Wales
    Verifizierte Postleitzahl
    Cardiff, Vereinigtes Königreich· Rekrutierung
  • Evelina London Children's Hospital
    Verifizierte Postleitzahl
    London, Vereinigtes Königreich· Rekrutierung
  • Kings College Krankenhaus
    Verifizierte Postleitzahl
    London, Vereinigtes Königreich· Rekrutierung
  • North Middlesex University Hospital
    Verifizierte Postleitzahl
    London, Vereinigtes Königreich· Rekrutierung
  • Das Royal London Hospital
    Verifizierte Postleitzahl
    London, Vereinigtes Königreich· Rekrutierung
  • University College London Hospital
    Verifizierte Postleitzahl
    London, Vereinigtes Königreich· Rekrutierung
  • Whittington Hospital
    Verifizierte Postleitzahl
    London, Vereinigtes Königreich· Rekrutierung
  • Royal Manchester Children's Hospital
    Verifizierte Postleitzahl
    Manchester, Vereinigtes Königreich· Rekrutierung
  • John Radcliffe Krankenhaus
    Verifizierte Postleitzahl
    Oxford, Vereinigtes Königreich· Rekrutierung

Häufige Fragen

What is Xromi?

Xromi is a liquid medicine that contains hydroxycarbamide, used to treat sickle cell disease.

Is this a new medicine being tested?

No, Xromi is already available. This study is observing how it works in real-life settings for very young children.

Wie lange wird mein Kind an der Studie teilnehmen?

Your child will be followed for 24 months (two years) from when they start Xromi or a similar 'start date' for children not taking it.

Will my child need extra doctor visits?

No, all information for the study will come from your child's regular doctor appointments and medical records.

Kann ich mein Kind aus der Studie herausnehmen?

Yes, you can decide to withdraw your child from the study at any time, and it won't affect their medical care.

Wie Sie mehr erfahren können

Hussain Mulla, PhD

Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.

Interessiert daran, teilzunehmen?

Registrieren Sie Ihr Interesse

Teilen Sie Ihre Details und das Forschungsteam für "PASS of Xromi Comparing Safety and Effectiveness in Children… wird Sie kontaktieren, wenn Sie möglicherweise infrage kommen. Sprechen Sie immer mit Ihrem Hausarzt, bevor Sie zustimmen, teilzunehmen.

Diskussion

Community-Diskussion

Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.